bicalutamide has been researched along with flutamide in 201 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (3.48) | 18.7374 |
| 1990's | 62 (30.85) | 18.2507 |
| 2000's | 79 (39.30) | 29.6817 |
| 2010's | 48 (23.88) | 24.3611 |
| 2020's | 5 (2.49) | 2.80 |
| Authors | Studies |
|---|---|
| Ackerman, JH; Bell, MR; Christiansen, RG; D'Ambra, TE; Herrmann, JL; Kullnig, RK; Mallamo, JP; Opalka, CJ; Snyder, BW; Winneker, RC | 1 |
| Chesterson, GJ; Crook, JW; Tucker, H | 1 |
| Brodie, AM; Chopra, P; Farquhar, R; Gediya, LK; Guo, Z; Handratta, VD; Kataria, R; Newman, D; Njar, VC; Qiu, Y; Vasaitis, TS | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Bailis, N; Baniahmad, A; Fousteris, MA; Giannis, A; Nikolaropoulos, SS; Roediger, J; Roell, D; Schubert, U | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Goto, M; Huang, R; Lee, KH; Lin, L; Morris-Natschke, SL; Ohkoshi, E; Shi, Q; Wada, K | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Chandolia, RK; Nieschlag, E; Simoni, M; Weinbauer, GF | 1 |
| Behre, HM; Chandolia, RK; Nieschlag, E; Simoni, M; Weinbauer, GF | 1 |
| Behre, HM; Chandolia, RK; Nieschlag, E; Weinbauer, GF | 1 |
| Schröder, FH | 2 |
| Barbolt, TA; Dube, JY; Egy, MA; Frenette, G; Juniewicz, PE; Tremblay, RR | 1 |
| Mowszowicz, I | 1 |
| Furr, BJ | 3 |
| Daricello, G; Pavone, C; Pavone-Macaluso, M; Romano, C; Serretta, V | 1 |
| Batzold, FH; Snyder, BW; Winneker, RC | 1 |
| Freeman, SN; Furr, BJ; Mainwaring, WI | 1 |
| Crawford, ED | 1 |
| Ebert, K; Knuppen, R; Michna, H; Vollmer, G | 1 |
| Block, N; Jones, J; Kolvenbag, G; Patterson, AL; Sarosdy, M; Schellhammer, P; Sharifi, R; Soloway, M; Venner, P; Vogelzang, N | 2 |
| Berrevoets, CA; Mulder, E; Veldscholte, J | 1 |
| Maucher, A; von Angerer, E | 1 |
| Gromoll, J; Nieschlag, E; Simoni, M; Weinbauer, GF | 1 |
| McLeod, DG | 1 |
| Matzkin, H; Soloway, MS | 1 |
| Kemppainen, JA; Wilson, EM | 1 |
| Denis, L; Mahler, C; Verhelst, J | 2 |
| Nazareth, LV; Weigel, NL | 1 |
| Jones, J; Kolvenbag, G; Patterson, AL; Sarosdy, M; Schellhammer, P; Sharifi, R; Soloway, MS; Venner, P; Vogelzang, N | 1 |
| Blackledge, G; Kolvenbag, G; Nash, A | 1 |
| Calandra, RS; Campo, S; Cigorraga, SB; Creus, S; Pellizzari, E; Rulli, SB | 1 |
| Payan, C; Zerbib, M | 1 |
| Block, NL; Chen, Y; Kolvenbag, GJ; Patterson, AL; Sarosdy, MF; Schellhammer, PF; Sharifi, R; Soloway, MS; Venner, PM; Vogelzang, NJ | 1 |
| Dole, EJ; Holdsworth, MT | 1 |
| Kaisary, AV | 1 |
| Jimenez, J; Luizzi, MF; Sonnenschein, C; Soto, AM; Szelei, J | 1 |
| Labrie, F; Simard, J; Singh, SM | 1 |
| Chen, Y; Furr, B; Haas, GP; Klein, E; Kolvenbag, GJ; Nieh, PT; Patterson, AL; Schellhammer, PF; Seabaugh, DR; Small, EJ; Venner, P; Wajsman, Z | 1 |
| Kylmala, T; Palmberg, C; Tammela, T | 1 |
| Johnson, H; McDermed, JE; Scholz, MC; Strum, SB; Tisman, G | 1 |
| Bartsch, G; Cronauer, MV; Culig, Z; Hittmair, A; Hobisch, A; Klocker, H; Radmayr, C; Zhang, J | 1 |
| Candas, B; Labrie, F; Simard, J; Singh, SM | 1 |
| Brett, C; Kelly, WK; Kolvenbag, G; Liebertz, C; Mazumdar, M; Scher, HI; Schwartz, L; Schwartz, M; Shapiro, L | 1 |
| Block, NL; Kolvenbag, GJ; Patterson, AL; Sarosdy, MF; Schellenger, JJ; Schellhammer, PF; Sharifi, R; Soloway, MS; Venner, PM; Vogelzang, NJ | 1 |
| Schellhammer, PF | 1 |
| Balk, S; Bubley, GJ; Constantine, M; DeWolf, W; Fenton, MA; Gaynes, L; Joyce, R; Kolvenbag, G; Rode, P; Taplin, ME | 1 |
| Candas, B; Chen, C; Labrie, C; Labrie, F; Luo, S; Martel, C; Singh, SM | 1 |
| Chodak, GW | 1 |
| Boccon-Gibod, L | 1 |
| Battmann, T; Bouchoux, F; Branche, C; Cerede, E; Gaillard-Kelly, M; Goubet, F; Philibert, D; Teutsch, G | 1 |
| Bonnet, P | 1 |
| Chang, C; Miyamoto, H; Wilding, G; Yeh, S | 1 |
| Block, NL; Chodak, GW; Klein, EA; Kolvenbag, GJ; Patterson, AL; Sarosdy, MF; Schellenger, JJ; Schellhammer, PF; Sharifi, R; Soloway, MS; Venner, PM; Vogelzang, NJ | 1 |
| Chatelain, C; Fourcade, RO | 1 |
| Chang, C; Lardy, H; Messing, E; Miyamoto, H; Yeh, S | 1 |
| Akakura, K; Furuya, Y; Ito, H | 1 |
| Edwards, JP; Farmer, LJ; Jones, TK; Marschke, KB; Pooley, CL; West, SJ | 1 |
| Candas, B; Labrie, F | 1 |
| Budman, DR; Kreis, W; Liu, XM; Wang, LG | 1 |
| Balk, SP; Bubley, GJ; Ko, YJ; Rajeshkumar, B; Small, EJ; Taplin, ME; Upton, M | 1 |
| Hackenberg, R; Loos, S; Schulz, KD | 1 |
| Furr, BJ; Kolvenbag, GJ | 1 |
| Block, NL; Kelley, RP; Kolvenbag, GJ; McLeod, DG; Patterson, AL; Sarosdy, MF; Schellhammer, PF; Sharifi, R; Soloway, MS; Venner, PM; Vogelzang, NJ | 1 |
| Andriole, GL; Bhayani, SB | 1 |
| Calandra, RS; Cónsole, GG; Gómez Dumm, CL; Riccillo, FL; Rulli, SB | 1 |
| Barichello, M; Battaglia, M; Boccardo, F; Carmignani, G; Comeri, G; Conti, G; Cruciani, G; Dammino, S; Delliponti, U; Ditonno, P; Ferraris, V; Lilliu, S; Montefiore, F; Portoghese, F; Rubagotti, A; Spano, G | 1 |
| Sarosdy, MF | 1 |
| Richie, JP | 1 |
| Bloemena, E; Hage, JJ; Kanhai, RC; Mulder, JW; van Diest, PJ | 1 |
| De Angelis, M; De Benedetto, G; Migliari, R; Murru, M; Muscas, G; Verdacchi, T | 1 |
| Carroll, K; Johnson, R; Kolvenbag, GJ; Sarosdy, MF; Schellhammer, PF | 1 |
| Lumbroso, S; Moras, D; Nicolas, JC; Poujol, N; Sultan, C; Tahiri, B; Wurtz, JM | 1 |
| Feek, U; Helpap, B; Kaulfuss, U; Köllermann, J; Köllermann, MW; Müller, H; Oehler, U | 1 |
| Iversen, P; Melezinek, I; Schmidt, A | 1 |
| Leibowitz, RL; Tucker, SJ | 1 |
| Calandra, RS; Cónsole, GM; Gómez Dumm, CL; Jurado, SB; Rulli, SB | 1 |
| Collette, L; Denis, LJ; Schröder, FH; Studer, UE; Sylvester, RJ | 1 |
| Iversen, P; Kolvenbag, GJ; Newling, DW | 1 |
| Baniahmad, A; Cato, AC; Dotzlaw, H; Iñiguez Lluhí, JA; Mink, S; Moehren, U | 1 |
| Furuya, Y; Fuse, H; Nagakawa, O; Nozaki, T | 1 |
| Furutani, T; Hashimoto, T; Kato, S; Koutoku, H; Kudoh, M; Shikama, H; Shimizu, Y; Tanimoto, K; Watanabe, T | 1 |
| Bartsch, G; Culig, Z; Godoy-Tundidor, S; Hobisch, A; Pfeil, K | 1 |
| Jänne, OA; Karvonen, U; Palvimo, JJ | 1 |
| Bellmunt, J; Morote, J | 1 |
| Iversen, P | 1 |
| Balk, SP | 1 |
| Bennett, CL; Raisch, DW; Sartor, O | 1 |
| Barichello, M; Battaglia, M; Boccardo, F; Carmignani, G; Comeri, G; Cortellini, P; Ferraris, V; Lilliu, S; Montefiore, F; Portoghese, F; Rigatti, P; Rubagotti, A; Usai, E | 1 |
| Dalton, JT; He, Y; Hong, SS; Kirkovsky, L; Marhefka, C; Miller, DD; Perera, MA; Stourman, N; Yin, D | 1 |
| Kanetake, H; Sakai, H | 1 |
| Bahnson, R; Bissonette, EA; Miller, NL; Theodorescu, D; Wilson, J | 1 |
| Maeda, O; Usami, M | 1 |
| Mizokami, A; Namiki, M | 1 |
| Anderson, J | 1 |
| Duncan, WE; Harding, P; Howard, RS; McLeod, DG; Preston, DM; Torréns, JI | 1 |
| Lou, YR; Nazarova, N; Pennanen, P; Qiao, S; Tuohimaa, P | 1 |
| Abdalla, I; Basu, A; Connell, PP; Jani, AB; Krauz, L; Vijayakumar, S | 1 |
| Skarda, J | 1 |
| Chen, F; Iwamoto, Y; Langenstroer, P; See, W; Zhang, G | 1 |
| Fukabori, Y; Honma, S; Kashiwagi, B; Ono, Y; Shibata, Y; Suzuki, K; Yamanaka, H | 1 |
| Arango, O; Bielsa, O; Cañis, D; Cortadellas, R; Gelabert-Mas, A; Lloreta-Trull, J; Lorente, JA | 1 |
| Budde, A; Caprano, J; Helpap, B; Hopfenmüller, W; Köllermann, J; Weidenfeld, H; Weidenfeld, M | 1 |
| Akakura, K; Ichikawa, T; Ito, H; Kojima, S; Shimbo, M; Suzuki, H | 1 |
| Cardi, A; Di Silverio, F; Sciarra, A | 1 |
| Aslan, P; Bryant, C; Bucci, J; Diamond, TH; Kersley, JH; Lynch, WB | 1 |
| Gardiner, RA; Green, HJ; Headley, BC; Mactaggart, P; Nicol, DL; Pakenham, KI; Swanson, C; Watson, R; Yaxley, J | 1 |
| Baltogiannis, D; Charalabopoulos, K; Giannakopoulos, X; Sofikitis, N | 1 |
| Bevan, CL; Cato, AC; Gamble, SC; Hanrahan, S; Hurst, HC; Totty, N; Waxman, J; Whitaker, HC | 1 |
| Lou, YR; Nazarova, N; Talonpoika, R; Tuohimaa, P | 1 |
| Chertin, B; Farkas, A; Fridmans, A; Gelber, H; Koulikov, D; Leiter, C; Lindenberg, T; Spitz, IM | 1 |
| Lehtovuori, PT; Nyrönen, TH; Söderholm, AA | 1 |
| Gratzle, J; Jani, AB; Myers, M | 1 |
| Gratzle, J; Jani, AB | 1 |
| Farla, P; Hersmus, R; Houtsmuller, AB; Trapman, J | 1 |
| Davis, NB; Ryan, CW; Stadler, WM; Vogelzang, NJ | 1 |
| Eto, H; Hara, I; Miyake, H | 1 |
| Akaza, H; Chodak, GW; Hirao, Y | 1 |
| Clarke, L; Gandhi, S; Hirsch, M; Penson, D; Ramsey, S; Veenstra, D | 1 |
| Hidalgo, A; Manso, G; Revuelta, P; Salgueiro, E; Thole, Z | 1 |
| Asim, M; Baniahmad, A; Dotzlaw, H; Papaioannou, M; Reeb, C | 1 |
| Arnold, JT; Blackman, MR; Le, H; McFann, KK | 1 |
| Fujisawa, M; Hara, I; Inoue, TA; Miyake, H; Sakai, I | 1 |
| Carroll, PR; Chen, MH; D'Amico, AV; McLeod, DG; Richie, JP; Tsai, HK | 1 |
| Chang, CY; Elbi, C; Hager, GL; Hendarwanto, A; Klokk, TI; Kurys, P; Nagaich, AK; Saatcioglu, F; Slagsvold, T | 1 |
| De Rosier, T; Eliason, HC; Ervin, KM; Gowda, K; Kupcho, KR; Marks, BD; Ozers, MS; Qadir, N; Riddle, SM; Shekhani, MS | 1 |
| Agarwal, A; Pahalajani, G; Raina, R; Zippe, C | 1 |
| Fuse, H; Hiyama, T; Ito, T; Kato, S; Kimura, K; Korenaga, S; Sakari, M | 1 |
| Hara, S; Hyochi, N; Isaacs, JT; Ishioka, J; Kageyama, Y; Kihara, K; Singh, P; Urushibara, M | 1 |
| Arichi, N; Ichikawa, Y; Kishikawa, H; Nishimura, K; Tokugawa, S; Yoshioka, I | 1 |
| Dong, Z; Lu, S; Wang, A | 1 |
| Dewilde, S; Kleinman, L; Lloyd, A; Penson, D | 1 |
| Slovin, SF | 1 |
| Jennrich, R; Johnson, H; Lam, R; Scholz, M; Strum, S; Trilling, T | 1 |
| Ebara, S; Hashine, K; Kobayashi, Y; Kumon, H; Manabe, D; Miki, K; Nasu, Y; Saika, T; Saito, S; Satoh, T; Tanimoto, R | 1 |
| Chapman, RA; Crawford, ED; Eisenberger, MA; Fontana, JA; Hussain, MH; Mills, GM; Parab, M; Raghavan, D; Sartor, AO; Tangen, CM | 1 |
| Belanger, A; Chertin, B; Farkas, A; Fridmans, A; Hartman, H; Labrie, F; Spitz, IM | 1 |
| Fujii, M; Fujisawa, M; Ichikawa, T; Kumon, H; Matsuda, T; Matsumoto, T; Miki, T; Miyake, H; Miyoshi, S; Okihara, K; Ozono, S; Suzuki, H; Takihana, Y; Usui, T | 1 |
| Endo, Y; Fijii, S; Goto, T; Ohta, K; Ohta, S; Suzuki, T | 1 |
| Baniahmad, A; Eskelinen, H; Lehtovuori, PT; Nyrönen, TH; Roell, D; Söderholm, AA; Viiliäinen, J | 1 |
| Kempkensteffen, C; Kleinschmidt, K; Köllermann, J; Pantel, K; Rau, T; Schostak, M; Weikert, S | 1 |
| Lenie, S; Smitz, J | 1 |
| Burri, RJ; Cesaretti, JA; Ho, AY; Stock, RG; Stone, NN | 1 |
| Brogley, M; Chinnaiyan, A; Dhanasekaran, S; Hofer, MD; Kuefer, R; Lapensee, EW; O'Mahony, OA; Pienta, KJ; Rehman, H; Robins, DM; Rubin, MA; Steinkamp, MP | 1 |
| Boelsterli, UA; Branham, WS; Chan, EC; Desai, VG; Kale, VM; Kashimshetty, R; Lee, T; Moland, CL; New, LS; Younis, H | 1 |
| Akdas, A; Bolla, M; Collette, L; de Reijke, TM; Gez, E; Kariakine, O; Kil, P; Mauer, ME; Musat, E; Oddens, J; Piérart, M; Poortmans, PM; Soete, G; Van den Bergh, AC; van der Steen-Banasik, EM; Van Tienhoven, G | 1 |
| Knudsen, KE; Scher, HI | 1 |
| Inoue, T; Kamba, T; Kamoto, T; Maeno, A; Nakamura, E; Ogawa, O; Shimizu, Y; Terada, N; Yoshida, T | 1 |
| Dubbink, HJ; Hersmus, R; Jenster, G; Lusher, SJ; Molier, M; Trapman, J; van de Wijngaart, DJ | 1 |
| Ahlgren, G; Angelsen, A; Bergh, A; Haugen, OA; Solberg, A; Tasdemir, I; Viset, T; Widmark, A | 1 |
| Keenan, DM; Liu, PY; Mielke, KL; Takahashi, PY; Veldhuis, JD; Weist, SM | 1 |
| Chen, N; Chen, XQ; Huang, R; Huang, Y; Li, X; Wei, Q; Xia, J; Yang, YR; Zeng, H; Zhang, P; Zhu, YC | 1 |
| Higashihara, E; Nutahara, K; Okegawa, T | 1 |
| Itoh, K; Kanayama, H; Kawabata, R; Oie, S; Oka, T; Takahashi, M | 1 |
| Kobayashi, M; Kurokawa, S; Morita, T; Nukui, A; Suzuki, K | 1 |
| Hara, T; Inoue, H; Ishizuya, Y; Okada, T; Takada, T; Ueda, T | 1 |
| Gui, M; He, L; Li, W; Long, Z; Zhong, K | 1 |
| Both, S; Guzzo, TJ; Haas, NB; Hwang, WT; Jang, JW; Vapiwala, N; Wein, AJ | 1 |
| Beard, CJ; Chen, MH; D'Amico, AV; Kantoff, PW; Loffredo, MJ; Martin, NE; Nguyen, PL | 1 |
| Ito, H; Kakehi, Y; Kitamura, Y; Manabe, Y; Masuda, N; Mishina, M; Okuno, H; Sakura, Y; Sugimoto, M; Taoka, R; Terai, A | 1 |
| Hagiwara, M; Hayakawa, N; Ito, Y; Maeda, T; Matsumoto, K; Nagata, H; Nakamura, S; Ninomiya, A; Tanaka, N | 1 |
| Culig, Z | 1 |
| Antes, G; Dahm, P; Grobe, HR; Kunath, F; Meerpohl, JJ; Motschall, E; Rücker, G; Wullich, B | 1 |
| Duensing, S; Grüllich, C; Hadaschik, BA; Höfner, T; Hohenfellner, M; Jäger, D; Pahernik, S; Vallet, S | 1 |
| Amin, MB; Balogh, AG; Bauman, GS; Chinn, DM; Dignam, JJ; Duclos, M; Gomella, LG; Gore, EM; Hunt, D; Lukka, HR; Pisansky, TM; Rosenthal, SA; Rotman, MZ; Sandler, HM; Seider, MJ; Shipley, WU | 1 |
| Dagvadorj, A; Ellsworth, E; Gu, L; Gupta, S; Hoang, DT; Koptyra, M; Leiby, B; Liao, Z; Merry, DE; Mirtti, T; Montie, H; Nevalainen, MT; Savolainen, S; Shen, F; Talati, PG; Tan, SH | 1 |
| Begum, S; Bevan, CL; Brooke, GN; Bryan, RA; Dart, DA; Fioretti, FM; Gamble, SC; Hough, MA; Odontiadis, M; Powell, SM; Wait, R; Waxman, J | 1 |
| Alvarez, A; Boladeras, A; Cabeza Rodríguez, MA; Calvo, FA; Casas, F; de Vidales, CM; Gonzalez San Segundo, C; Guerrero, A; Macias, V; Maldonado, X; Pedro Olive, A; Perez de la Haza, A; Vazquez de la Torre, ML; Villà, S; Zapatero, A | 1 |
| Anai, S; Fujimoto, K; Miyake, M; Nakai, Y; Tanaka, N; Tatsumi, Y | 1 |
| Awrey, S; Azad, AA; Cherkasov, A; Chi, KN; Collins, CC; Gleave, ME; Lallous, N; LeBihan, S; Leblanc, E; Murillo, J; Rennie, PS; Singh, K; Tse, R; Volik, SV; Wyatt, AW | 1 |
| Celma, A; Morote, J; Planas, J; Regis, L | 1 |
| Bogner, J; Hickson, I; Romer, T; Yurlova, L; Zolghadr, K | 1 |
| Hara, N; Ishizaki, F; Nishiyama, T; Takeda, K; Tasaki, M; Tomita, Y | 1 |
| Scholz, MC; Strum, SB | 1 |
| El-Shishtawy, KA; Ide, H; Kashiwagi, E; Kawahara, T; Li, Y; Miyamoto, H; Reis, LO; Zheng, Y | 1 |
| Kawahara, T; Miyoshi, Y; Noguchi, K; Otani, M; Teranishi, J; Uemura, H; Yamanaka, S; Yao, M; Yokomizo, Y | 1 |
| Cassidy-Bushrow, AE; Haque, R; Keating, NL; Potosky, AL; Tsai, HT; UlcickasYood, M; Van Den Eeden, SK; Xu, X | 1 |
| Athersuch, TJ; Bradshaw, PR; Butler, PJ; Dilworth, C; Gill, RU; Wilson, ID | 1 |
| García-Perdomo, HA; Reis, LO; Zani, EL | 1 |
| Anai, S; Fujimoto, K; Inoue, T; Miyake, M; Nakai, Y; Tanaka, N | 1 |
| Bryant, AK; Deka, R; McKay, R; Murphy, JD; Nalawade, V; Rose, BS; Sarkar, RR; Simpson, DR | 1 |
| Antosik, A; Chmiel, K; Jachowicz, R; Jurkiewicz, K; Kurek, M; Pacult, J; Paluch, M; Rams-Baron, M; Szafraniec, J | 1 |
| Azhagiya Singam, ER; Durkin, KA; La Merrill, MA; Smith, MT; Tachachartvanich, P | 1 |
| Fukuoka, K; Hayashi, T; Inoue, S; Kadonishi, Y; Kajiwara, M; Kobayashi, K; Matsubara, A; Mita, K; Nagamatsu, H; Shigeta, M; Tacho, T; Teishima, J | 1 |
| Adachi, T; Deguchi, T; Harimoto, K; Hase, T; Iguchi, T; Ishii, K; Iwamoto, K; Iwata, H; Kanamaru, T; Kato, M; Machida, Y; Morimoto, K; Nakatani, T; Ohmachi, T; Takegaki, Y; Tamada, S; Tashiro, K; Yamamoto, S; Yasuda, S | 1 |
| Akamatsu, S; Fujimoto, Y; Inoue, T; Kimura, T; Kobayashi, T; Matsubara, N; Mori, K; Murakami, K; Ogawa, O; Terada, N | 1 |
| Funahashi, Y; Gotoh, M; Matsukawa, Y; Muramatsu, T; Sassa, N; Yamamoto, A | 1 |
| Chen, C; Li, J; Shen, P; Wu, B; Wu, F; Xu, T; Yin, X; Yu, L | 1 |
| Ijiri, Y; Kato, R; Kohda, Y; Noda, T; Tanaka, S; Yamada, T | 1 |
35 review(s) available for bicalutamide and flutamide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Pure antiandrogens as monotherapy in prospective studies of prostatic carcinoma.
Topics: Androgen Antagonists; Anilides; Animals; Cyproterone; Cyproterone Acetate; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Nitriles; Prospective Studies; Prostatic Neoplasms; Tosyl Compounds | 1990 |
[Antiandrogens. Mechanisms and paradoxical effects].
Topics: 5-alpha Reductase Inhibitors; Androgen Antagonists; Androgens; Anilides; Cimetidine; Cyproterone; Cyproterone Acetate; Flutamide; Humans; Nitriles; Spironolactone; Tosyl Compounds | 1989 |
Casodex: preclinical studies and controversies.
Topics: Androgen Antagonists; Anilides; Animals; Dogs; Endocrine Glands; Flutamide; Genitalia, Male; Humans; In Vitro Techniques; Male; Nitriles; Prostate; Prostatic Neoplasms; Rats; Receptors, Androgen; Tosyl Compounds | 1995 |
Antiandrogenic drugs.
Topics: Androgen Receptor Antagonists; Anilides; Cyproterone Acetate; Diethylstilbestrol; Drug Administration Schedule; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Megestrol; Megestrol Acetate; Nitriles; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Tosyl Compounds | 1993 |
Antiandrogenic agents as monotherapy in advanced prostatic carcinoma.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Cyproterone Acetate; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Neoplasm Staging; Nitriles; Prognosis; Prostatic Neoplasms; Testosterone; Tosyl Compounds | 1993 |
Bicalutamide: a new antiandrogen for use in combination with castration for patients with advanced prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Flutamide; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Orchiectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Tosyl Compounds | 1996 |
Nilutamide: an antiandrogen for the treatment of prostate cancer.
Topics: Androgen Antagonists; Anilides; Flutamide; Half-Life; Humans; Imidazoles; Imidazolidines; Male; Nitriles; Orchiectomy; Prostatic Neoplasms; Structure-Activity Relationship; Tosyl Compounds | 1997 |
Are non-steroidal anti-androgens appropriate as monotherapy in advanced prostate cancer?
Topics: Androgen Antagonists; Anilides; Clinical Trials as Topic; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Nitriles; Prostatic Neoplasms; Survival Rate; Tosyl Compounds; Treatment Outcome | 1998 |
Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Clinical Trials as Topic; Cyproterone; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1998 |
The place and the results of monotherapy.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Cyproterone Acetate; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1998 |
Androgen deprivation for prostatic carcinoma: a rationale for choosing components.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Flutamide; Goserelin; Humans; Imidazoles; Imidazolidines; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1998 |
[Steroidal and nonsteroidal antiandrogens: chemical structures, mechanisms of action and clinical applications].
Topics: Androgen Antagonists; Anilides; Chlormadinone Acetate; Flutamide; Humans; Male; Neoplasms, Hormone-Dependent; Nitriles; Prostatic Hyperplasia; Prostatic Neoplasms; Tosyl Compounds | 1998 |
Antiandrogens as monotherapy for prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Cyproterone Acetate; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1998 |
Hormonal manipulation for rising PSA after radical prostatectomy.
Topics: Androgen Antagonists; Anilides; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Flutamide; Humans; Male; Neoplasm Recurrence, Local; Nitriles; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Tosyl Compounds | 1999 |
Which is the optimal antiandrogen for use in combined androgen blockade of advanced prostate cancer? The transition from a first- to second-generation antiandrogen.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Combined Modality Therapy; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Neoplasm Staging; Nitriles; Orchiectomy; Prostatic Neoplasms; Tosyl Compounds | 1999 |
Anti-androgens and other hormonal therapies for prostate cancer.
Topics: Androgen Antagonists; Androgens; Anilides; Biomarkers, Tumor; Flutamide; Humans; Male; Neoplasms, Hormone-Dependent; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Tamoxifen; Tosyl Compounds | 1999 |
Antiandrogens: a summary review of pharmacodynamic properties and tolerability in prostate cancer therapy.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Anilides; Antineoplastic Agents, Hormonal; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1999 |
Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function.
Topics: Androgen Antagonists; Anilides; Erectile Dysfunction; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Nitriles; Prostatic Neoplasms; Quality of Life; Sexuality; Tosyl Compounds | 2001 |
Antiandrogen monotherapy: a new form of treatment for patients with prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Meta-Analysis as Topic; Nitriles; Orchiectomy; Prostatic Neoplasms; Quality of Life; Tosyl Compounds; Treatment Outcome | 2001 |
Antiandrogen monotherapy: indications and results.
Topics: Aged; Androgen Antagonists; Anilides; Castration; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Middle Aged; Nitriles; Patient Compliance; Prostatic Neoplasms; Quality of Life; Tosyl Compounds; Treatment Outcome | 2002 |
Androgen receptor as a target in androgen-independent prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Flutamide; Humans; Male; Mutation; Nitriles; Prostatectomy; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Tosyl Compounds | 2002 |
[First line therapy in the treatment of metastatic prostate cancer].
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Flutamide; Gonadotropin-Releasing Hormone; Humans; Male; Nitriles; Orchiectomy; Prostatic Neoplasms; Quality of Life; Tosyl Compounds | 2003 |
[Antiandrogen in prostate cancer].
Topics: Androgen Antagonists; Anilides; Animals; Antineoplastic Agents, Hormonal; Drug Therapy, Combination; Flutamide; Humans; Male; Nitriles; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Rats; Receptors, Androgen; Tosyl Compounds | 2002 |
[Total androgen blockade].
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Castration; Chlormadinone Acetate; Drug Therapy, Combination; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Nitriles; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Tosyl Compounds | 2002 |
The role of antiandrogen monotherapy in the treatment of prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Drug Administration Schedule; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Nitriles; Patient Compliance; Prostatic Neoplasms; Survival Analysis; Tosyl Compounds | 2003 |
Antiandrogen monotherapy: recommendations for the treatment of prostate cancer.
Topics: Androgen Antagonists; Anilides; Chemotherapy, Adjuvant; Cyproterone Acetate; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Nitriles; Orchiectomy; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Tosyl Compounds | 2004 |
Monotherapy in advanced prostate cancer: an overview.
Topics: Adenocarcinoma; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Cyproterone Acetate; Dihydrotestosterone; Estrogens; Flutamide; Gonadotropin-Releasing Hormone; Humans; Imidazolidines; Male; Nitriles; Orchiectomy; Palliative Care; Progesterone Congeners; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Testosterone; Tosyl Compounds | 2004 |
[Usefulness and positioning of MAB therapy for prostate cancer].
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Drug Administration Schedule; Flutamide; Gonadotropin-Releasing Hormone; Humans; Male; Nitriles; Prostatic Neoplasms; Quality of Life; Survival Analysis; Survival Rate; Tosyl Compounds | 2005 |
Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Anilides; Flutamide; Humans; Male; Nitriles; Prostatic Neoplasms; Protein Structure, Tertiary; Receptors, Androgen; Signal Transduction; Tosyl Compounds | 2009 |
Third-line hormonal therapy to treat prostate cancer relapse after initial and second-line hormonal therapy: report of 52 cases and literature review.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Chlormadinone Acetate; Cohort Studies; Flutamide; Gonadotropin-Releasing Hormone; Humans; Kallikreins; Male; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Tosyl Compounds; Treatment Outcome | 2014 |
Targeting the androgen receptor in prostate cancer.
Topics: Androgen Antagonists; Anilides; Antibodies, Neutralizing; Anticarcinogenic Agents; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Curcumin; Flutamide; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Male; Molecular Targeted Therapy; Nitriles; Oligonucleotides, Antisense; Phenylthiohydantoin; Phosphatidylinositol 3-Kinases; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Steroid 17-alpha-Hydroxylase; Tosyl Compounds | 2014 |
Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Disease Progression; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Medication Adherence; Nitriles; Orchiectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Tosyl Compounds; Triptorelin Pamoate | 2014 |
Measurement of serum testosterone during androgenic suppression in patients with prostate cancer: A systematic review.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Flutamide; Gonadotropin-Releasing Hormone; Humans; Male; Nitriles; Oligopeptides; Orchiectomy; Prostatic Neoplasms; Testosterone; Tosyl Compounds | 2016 |
Estrogen therapy in patients with prostate cancer: a contemporary systematic review.
Topics: Anilides; Antineoplastic Agents, Hormonal; Diethylstilbestrol; Estrogens, Non-Steroidal; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Nitriles; Orchiectomy; Prostatic Neoplasms; Tosyl Compounds | 2018 |
25 trial(s) available for bicalutamide and flutamide
| Article | Year |
|---|---|
Pure antiandrogens as monotherapy in prospective studies of prostatic carcinoma.
Topics: Androgen Antagonists; Anilides; Animals; Cyproterone; Cyproterone Acetate; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Nitriles; Prospective Studies; Prostatic Neoplasms; Tosyl Compounds | 1990 |
A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Confidence Intervals; Double-Blind Method; Flutamide; Follow-Up Studies; Goserelin; Humans; Leuprolide; Male; Middle Aged; Nitriles; Proportional Hazards Models; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Regression Analysis; Survival Rate; Tosyl Compounds; Treatment Failure | 1995 |
Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Flutamide; Follow-Up Studies; Goserelin; Humans; Leuprolide; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1996 |
A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Drug Synergism; Flutamide; Follow-Up Studies; Goserelin; Humans; Male; Nitriles; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Survival Analysis; Tosyl Compounds | 1996 |
Bicalutamide: a new antiandrogen for use in combination with castration for patients with advanced prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Flutamide; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Orchiectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Tosyl Compounds | 1996 |
A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Controlled Clinical Trials as Topic; Flutamide; Gonadotropin-Releasing Hormone; Humans; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1996 |
A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group.
Topics: Adenocarcinoma; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Double-Blind Method; Flutamide; Goserelin; Humans; Leuprolide; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1996 |
Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Flutamide; Follow-Up Studies; Goserelin; Humans; Leuprolide; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Survival Rate; Tosyl Compounds | 1997 |
Comparison of goserelin and leuprolide in combined androgen blockade therapy.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Double-Blind Method; Flutamide; Goserelin; Humans; Leuprolide; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Survival Rate; Tosyl Compounds | 1998 |
Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues. The Casodex Combination Study Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Black People; Bone Neoplasms; Cohort Studies; Disease Progression; Disease-Free Survival; Double-Blind Method; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Tosyl Compounds; White People | 1999 |
Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Consumer Product Safety; Disease Progression; Disease-Free Survival; Erectile Dysfunction; Flutamide; Goserelin; Humans; Italy; Male; Middle Aged; Nitriles; Proportional Hazards Models; Prostatic Neoplasms; Quality of Life; Survival Rate; Tosyl Compounds | 1999 |
Does prolonged combined androgen blockade have survival benefits over short-term combined androgen blockade therapy?
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Drug Administration Schedule; Drug Therapy, Combination; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Survival Rate; Tosyl Compounds | 2000 |
Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Finasteride; Flutamide; Follow-Up Studies; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Middle Aged; Neoplasm Staging; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome | 2001 |
Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: updated results of a multicentric trial.
Topics: Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Flutamide; Goserelin; Humans; Male; Middle Aged; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Tosyl Compounds; Treatment Outcome | 2002 |
A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy.
Topics: Adult; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Disease Progression; Flutamide; Humans; Imidazolidines; Male; Middle Aged; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds; Treatment Failure | 2005 |
Long-term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1-2): a retrospective study.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Flutamide; Gonadotropin-Releasing Hormone; Humans; Imidazolidines; Leuprolide; Male; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Tosyl Compounds | 2007 |
The efficacy of neoadjuvant androgen deprivation therapy as a prostate volume reduction before brachytherapy for clinically localized prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Brachytherapy; Chemotherapy, Adjuvant; Combined Modality Therapy; Flutamide; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Nitriles; Prostate; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome; Ultrasonography | 2007 |
Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Bone Neoplasms; Disease-Free Survival; Flutamide; Gonadotropin-Releasing Hormone; Humans; Imidazolidines; Male; Middle Aged; Nitriles; Orchiectomy; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Substance Withdrawal Syndrome; Survival Rate; Tosyl Compounds | 2008 |
Duration of androgen suppression in the treatment of prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Flutamide; Follow-Up Studies; Gonadotropin-Releasing Hormone; Heart Diseases; Humans; Male; Middle Aged; Nitriles; Proportional Hazards Models; Prostatic Neoplasms; Quality of Life; Radiotherapy, Conformal; Tosyl Compounds; Treatment Failure | 2009 |
Residual prostate cancer in patients treated with endocrine therapy with or without radical radiotherapy: a side study of the SPCG-7 randomized trial.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Biopsy; Combined Modality Therapy; Disease Progression; Flutamide; Follow-Up Studies; Humans; Leuprolide; Male; Neoplasm Recurrence, Local; Neoplasm, Residual; Nitriles; Odds Ratio; Prospective Studies; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds | 2011 |
Age disrupts androgen receptor-modulated negative feedback in the gonadal axis in healthy men.
Topics: Adult; Age Factors; Aged; Androgen Antagonists; Anilides; Central Nervous System; Cross-Over Studies; Double-Blind Method; Estradiol; Feedback; Flutamide; Humans; Hypothalamo-Hypophyseal System; Linear Models; Luteinizing Hormone; Male; Middle Aged; Nitriles; Pituitary-Adrenal System; Prospective Studies; Receptors, Androgen; Sex Hormone-Binding Globulin; Testosterone; Tosyl Compounds; Young Adult | 2010 |
Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Disease-Free Survival; Flutamide; Follow-Up Studies; Goserelin; Humans; Leuprolide; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy; Time Factors; Tosyl Compounds; Treatment Outcome | 2015 |
High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Chemoradiotherapy; Disease-Free Survival; Drug Administration Schedule; Flutamide; Gonadotropin-Releasing Hormone; Hospitals, University; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Nitriles; Prostatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Conformal; Risk Factors; Spain; Time Factors; Tosyl Compounds; Treatment Outcome | 2015 |
A Randomized Control Trial Comparing the Efficacy of Antiandrogen Monotherapy: Flutamide vs. Bicalutamide.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androstenedione; Anilides; Dehydroepiandrosterone; Flutamide; Humans; Male; Neoplasm Staging; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Testosterone; Tosyl Compounds | 2015 |
Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: the OCUU-CRPC study.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Flutamide; Humans; Kallikreins; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Progression-Free Survival; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Tosyl Compounds; Treatment Outcome | 2020 |
143 other study(ies) available for bicalutamide and flutamide
| Article | Year |
|---|---|
Antiandrogenic steroidal sulfonylpyrazoles.
Topics: Androgen Antagonists; Animals; Male; Molecular Structure; Orchiectomy; Organ Size; Pregnanes; Prostate; Pyrazoles; Rats; Rats, Inbred Strains; Receptors, Androgen; Structure-Activity Relationship; Testosterone; X-Ray Diffraction | 1990 |
Nonsteroidal antiandrogens. Synthesis and structure-activity relationships of 3-substituted derivatives of 2-hydroxypropionanilides.
Topics: Androgen Antagonists; Anilides; Animals; Chemical Phenomena; Chemistry; Flutamide; Luteinizing Hormone; Male; Nitriles; Prostate; Rats; Seminal Vesicles; Structure-Activity Relationship; Sulfones; Sulfoxides; Testosterone; Tosyl Compounds | 1988 |
Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
Topics: 5-alpha Reductase Inhibitors; Androgen Antagonists; Androstadienes; Animals; Antineoplastic Agents; Azoles; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Humans; Isoenzymes; Male; Mice; Mice, SCID; Mutation; Prostatic Neoplasms; Pyrazines; Radioligand Assay; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Structure-Activity Relationship; Tissue Distribution; Transcription, Genetic; Transcriptional Activation; Xenograft Model Antitumor Assays | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
20-Aminosteroids as a novel class of selective and complete androgen receptor antagonists and inhibitors of prostate cancer cell growth.
Topics: Androgen Receptor Antagonists; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Male; Molecular Conformation; Mutation; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stereoisomerism; Steroids; Structure-Activity Relationship | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Antitumor agents 290. Design, synthesis, and biological evaluation of new LNCaP and PC-3 cytotoxic curcumin analogs conjugated with anti-androgens.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Curcumin; Drug Design; Flutamide; Humans; Male; Nitriles; Prostatic Neoplasms; Pseudopodia; Structure-Activity Relationship; Tosyl Compounds | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Microheterogeneity of pituitary follicle-stimulating hormone in male rats: differential effects of the chronic androgen deprivation induced by castration or androgen blockade.
Topics: Androgen Antagonists; Anilides; Animals; Biological Assay; Flutamide; Follicle Stimulating Hormone; Isoelectric Point; Male; Nitriles; Orchiectomy; Pituitary Gland; Radioimmunoassay; Rats; Rats, Wistar; Tosyl Compounds | 1992 |
Comparative effects of chronic administration of the non-steroidal antiandrogens flutamide and Casodex on the reproductive system of the adult male rat.
Topics: Androgen Antagonists; Androgens; Anilides; Animals; Epididymis; Flutamide; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; Luteinizing Hormone; Male; Nitriles; Organ Size; Pituitary Gland; Rats; Rats, Inbred Strains; Seminal Vesicles; Spermatogenesis; Testis; Tosyl Compounds | 1991 |
Evaluation of a peripherally selective antiandrogen (Casodex) as a tool for studying the relationship between testosterone and spermatogenesis in the rat.
Topics: Androgen Antagonists; Anilides; Animals; Epididymis; Flutamide; Follicle Stimulating Hormone; Luteinizing Hormone; Male; Mesylates; Nitriles; Organ Size; Pituitary Gland; Rats; Rats, Inbred Strains; Seminal Vesicles; Spermatogenesis; Testis; Testosterone; Tosyl Compounds | 1991 |
Effects of androgen and antiandrogen treatment on canine prostatic arginine esterase.
Topics: 5-alpha Reductase Inhibitors; Androgen Antagonists; Androgens; Androstane-3,17-diol; Androstenes; Anilides; Animals; Azasteroids; Capsules; Carboxylic Ester Hydrolases; Dogs; Dose-Response Relationship, Drug; Estradiol; Finasteride; Flutamide; Hyperplasia; Injections, Intramuscular; Male; Nitriles; Pregnanes; Prostate; Prostatectomy; Pyrazoles; Tosyl Compounds | 1990 |
"Casodex" (ICI 176,334)--a new, pure, peripherally-selective anti-androgen: preclinical studies.
Topics: Androgen Antagonists; Anilides; Animals; Cyproterone; Cyproterone Acetate; Dogs; Flutamide; Imidazoles; Imidazolidines; Male; Nitriles; Prostatic Neoplasms; Rats; Tosyl Compounds | 1989 |
[Antiandrogens in monotherapy or combined therapy for treatment of advanced cancer of the prostate].
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Combined Modality Therapy; Cyproterone; Cyproterone Acetate; Flutamide; Follow-Up Studies; Humans; Imidazoles; Imidazolidines; Male; Middle Aged; Neoplasm Staging; Nitriles; Orchiectomy; Prostatic Neoplasms; Tosyl Compounds | 1989 |
Endocrine profile of Win 49596 in the rat: a novel androgen receptor antagonist.
Topics: Androgen Receptor Antagonists; Anilides; Animals; Estrogen Antagonists; Female; Flutamide; Genitalia, Male; Male; Nitriles; Orchiectomy; Pregnanes; Progesterone; Pyrazoles; Rabbits; Rats; Rats, Inbred Strains; Testosterone; Tosyl Compounds | 1989 |
A possible explanation for the peripheral selectivity of a novel non-steroidal pure antiandrogen, Casodex (ICI 176,334).
Topics: Androgen Antagonists; Anilides; Animals; Flutamide; Luteinizing Hormone; Male; Nitriles; Rats; Rats, Inbred Strains; Receptors, Androgen; Testosterone; Tissue Distribution; Tosyl Compounds | 1989 |
ICI 176,334: a novel non-steroidal, peripherally-selective antiandrogen.
Topics: Androgen Antagonists; Anilides; Animals; Cyproterone; Cyproterone Acetate; Dogs; Flutamide; Imidazoles; Imidazolidines; Male; Nitriles; Prostate; Radioligand Assay; Rats; Receptors, Androgen; Seminal Vesicles; Testosterone; Tosyl Compounds | 1988 |
A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Controlled Clinical Trials as Topic; Flutamide; Goserelin; Humans; Leuprolide; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1995 |
Androgen ablation induces tenascin expression in the rat prostate.
Topics: Androgen Antagonists; Anilides; Animals; Cell Adhesion Molecules, Neuronal; Cyproterone Acetate; Extracellular Matrix Proteins; Flutamide; Male; Nitriles; Orchiectomy; Prostate; Rats; Rats, Wistar; Tenascin; Testosterone; Tosyl Compounds | 1994 |
Effects of antiandrogens on transformation and transcription activation of wild-type and mutated (LNCaP) androgen receptors.
Topics: Adenocarcinoma; Alanine; Amino Acid Sequence; Androgen Antagonists; Anilides; Animals; Blotting, Western; Cell Line; Cell Nucleus; Chloramphenicol O-Acetyltransferase; Cyproterone Acetate; Dose-Response Relationship, Drug; Flutamide; Humans; Male; Metribolone; Mutagenesis, Site-Directed; Nitriles; Point Mutation; Prostatic Neoplasms; Receptors, Androgen; Recombinant Proteins; Threonine; Tosyl Compounds; Transcription, Genetic; Transfection; Transformation, Genetic; Tumor Cells, Cultured | 1993 |
Antiproliferative activity of casodex (ICI 176.334) in hormone-dependent tumours.
Topics: Androgen Antagonists; Anilides; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Diethylstilbestrol; Female; Flutamide; Male; Mammary Neoplasms, Experimental; Mice; Neoplasms, Hormone-Dependent; Nitriles; Prostatic Neoplasms; Rats; Rats, Inbred F344; Receptors, Androgen; Testosterone; Tosyl Compounds; Tumor Cells, Cultured | 1993 |
Effects of antiandrogens and ethane dimethane sulphonate (EDS) on gene expression, free subunits, bioactivity and secretion of pituitary gonadotrophins in male rats.
Topics: Androgen Antagonists; Anilides; Animals; Flutamide; Follicle Stimulating Hormone; Follicle Stimulating Hormone, beta Subunit; Gene Expression; Gonadotropin-Releasing Hormone; Gonadotropins, Pituitary; Luteinizing Hormone; Male; Mesylates; Nitriles; Orchiectomy; Pituitary Gland; Rats; Rats, Sprague-Dawley; RNA, Messenger; Testosterone; Tosyl Compounds | 1993 |
Agonist and antagonist activities of hydroxyflutamide and Casodex relate to androgen receptor stabilization.
Topics: Androgen Antagonists; Anilides; Binding, Competitive; Cells, Cultured; Flutamide; Nitriles; Receptors, Androgen; Tosyl Compounds | 1996 |
New molecules and treatment modulation in advanced prostatic cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Flutamide; Humans; Imidazoles; Male; Nitriles; Prostatic Neoplasms; Retinoids; Somatostatin; Suramin; Tosyl Compounds | 1996 |
Activation of the human androgen receptor through a protein kinase A signaling pathway.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Anilides; Animals; Cell Line; Cell Nucleus; Chlorocebus aethiops; Colforsin; Cyclic AMP-Dependent Protein Kinases; DNA-Binding Proteins; Enzyme Inhibitors; Flutamide; Gene Expression Regulation; Humans; Male; Nitriles; Receptors, Androgen; Receptors, Progesterone; Signal Transduction; Structure-Activity Relationship; Tosyl Compounds; Transcription, Genetic | 1996 |
Immunological and biological activities of pituitary FSH isoforms in prepubertal male rats: effect of antiandrogens.
Topics: Androgen Antagonists; Anilides; Animals; Dose-Response Relationship, Drug; Flutamide; Follicle Stimulating Hormone; Immunohistochemistry; Male; Nitriles; Pituitary Gland; Rats; Rats, Sprague-Dawley; Tosyl Compounds | 1996 |
Antiandrogen monotherapy in the management of advanced prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Nitriles; Orchiectomy; Palliative Care; Prostatic Neoplasms; Tosyl Compounds | 1997 |
Androgen-induced inhibition of proliferation in human breast cancer MCF7 cells transfected with androgen receptor.
Topics: Androgen Antagonists; Androgens; Anilides; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Division; Dihydrotestosterone; Dose-Response Relationship, Drug; Female; Flutamide; Humans; In Vitro Techniques; Metribolone; Nandrolone; Nitriles; Receptors, Androgen; Testosterone; Testosterone Congeners; Tosyl Compounds; Transfection; Tumor Cells, Cultured | 1997 |
Comparison of in vitro effects of the pure antiandrogens OH-flutamide, Casodex, and nilutamide on androgen-sensitive parameters.
Topics: Androgen Antagonists; Anilides; Animals; Apolipoproteins; Apolipoproteins D; Breast Neoplasms; Carrier Proteins; Cell Division; Dose-Response Relationship, Drug; Flutamide; Glycoproteins; Humans; Imidazoles; Imidazolidines; Membrane Transport Proteins; Mice; Neoplasm Proteins; Nitriles; Tosyl Compounds; Tumor Cells, Cultured | 1997 |
Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Flutamide; Humans; Male; Middle Aged; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds | 1997 |
Reduction of flutamide-induced alanine aminotransferase elevation after replacement by bicalutamide in a patient with N+ disease treated with maximal androgen blockade as a primary treatment.
Topics: Alanine Transaminase; Androgen Antagonists; Anilides; Antineoplastic Agents; Flutamide; Humans; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1997 |
Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade.
Topics: Age Factors; Aged; Anemia; Anilides; Antineoplastic Combined Chemotherapy Protocols; Finasteride; Flutamide; Hemoglobins; Humans; Male; Nitriles; Prospective Studies; Prostatic Neoplasms; Testosterone; Time Factors; Tosyl Compounds | 1997 |
Synergistic activation of androgen receptor by androgen and luteinizing hormone-releasing hormone in prostatic carcinoma cells.
Topics: Androgen Antagonists; Anilides; Bucladesine; Cell Line; Chloramphenicol O-Acetyltransferase; Cyclic AMP; Flutamide; Genes, Reporter; Gonadotropin-Releasing Hormone; Humans; Kinetics; Male; Metribolone; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Recombinant Fusion Proteins; Testosterone Congeners; Tosyl Compounds; Transcriptional Activation; Transfection; Tumor Cells, Cultured | 1997 |
Estimated potency of Casodex: a problematic design.
Topics: Androgen Antagonists; Anilides; Flutamide; Humans; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1997 |
Bicalutamide for advanced prostate cancer: the natural versus treated history of disease.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Anilides; Antineoplastic Agents, Hormonal; Bone and Bones; Bone Neoplasms; Disease Progression; Flutamide; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Radionuclide Imaging; Tosyl Compounds | 1997 |
Fulminant hepatic failure associated with bicalutamide.
Topics: Androgen Antagonists; Anilides; Cyproterone Acetate; Flutamide; Hepatic Encephalopathy; Humans; Nitriles; Tosyl Compounds | 1997 |
High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Flutamide; Humans; Male; Middle Aged; Nitriles; Pilot Projects; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds | 1998 |
Daily dosing with flutamide or Casodex exerts maximal antiandrogenic activity.
Topics: Androgen Antagonists; Androstenedione; Anilides; Animals; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Dose-Response Relationship, Drug; Drug Implants; Flutamide; Male; Mice; Mice, Inbred Strains; Nitriles; Orchiectomy; Organ Size; Prostate; Random Allocation; Rats; Rats, Sprague-Dawley; Time Factors; Tosyl Compounds | 1997 |
Bicalutamide-associated fulminant hepatic failure.
Topics: Androgen Antagonists; Anilides; Flutamide; Hepatic Encephalopathy; Humans; Liver; Nitriles; Tosyl Compounds | 1997 |
Pharmacological profile of RU 58642, a potent systemic antiandrogen for the treatment of androgen-dependent disorders.
Topics: Androgen Antagonists; Anilides; Animals; Flutamide; Genital Diseases, Male; Genitalia, Male; Hydantoins; Imidazoles; Imidazolidines; In Vitro Techniques; Male; Nitriles; Orchiectomy; Organ Size; Rats; Rats, Sprague-Dawley; Receptors, Androgen; Testosterone; Tosyl Compounds | 1998 |
Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells.
Topics: Androgen Antagonists; Androgens; Anilides; Cyproterone Acetate; Drug Interactions; Flutamide; Humans; Imidazoles; Male; Mifepristone; Nitriles; Nuclear Receptor Coactivators; Oncogene Proteins; Prostatic Neoplasms; Protein Binding; Protein Conformation; Tosyl Compounds; Trans-Activators; Transcription Factors; Transcriptional Activation; Tumor Cells, Cultured | 1998 |
Delta5-androstenediol is a natural hormone with androgenic activity in human prostate cancer cells.
Topics: Androgens; Androstane-3,17-diol; Androstenediol; Anilides; Flutamide; Humans; Male; Mutation; Nitriles; Nuclear Receptor Coactivators; Oncogene Proteins; Prostatic Neoplasms; Protein Conformation; Receptors, Androgen; Steroids; Testosterone; Tosyl Compounds; Trans-Activators; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transfection; Tumor Cells, Cultured | 1998 |
New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g] quinolinone.
Topics: Androgen Antagonists; Anilides; Animals; Cell Line; Drug Design; Flutamide; Gene Expression Regulation; Humans; Molecular Structure; Nitriles; Pyrrolidines; Quinolines; Quinolones; Receptors, Androgen; Recombinant Proteins; Structure-Activity Relationship; Tosyl Compounds; Transcription, Genetic; Transfection | 1998 |
Bicalutamide versus flutamide in combination therapy.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Flutamide; Humans; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1999 |
Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity.
Topics: Androgen Antagonists; Androgens; Anilides; Animals; Base Sequence; Dihydrotestosterone; Estradiol; Estramustine; Flutamide; Humans; Ligands; Male; Molecular Sequence Data; Nitriles; Phosphorylation; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; RNA, Messenger; Tosyl Compounds; Tumor Cells, Cultured | 1999 |
Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Biopsy; Bone Marrow; Bone Marrow Neoplasms; Codon; DNA Mutational Analysis; Flutamide; Humans; Male; Mutation; Neoplasms, Hormone-Dependent; Nitriles; Prostatic Neoplasms; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; Tosyl Compounds | 1999 |
Regulation of GCDFP-15 expression in human mammary cancer cells.
Topics: Androgen Antagonists; Anilides; Apolipoproteins; Apolipoproteins D; Breast Neoplasms; Carrier Proteins; Cell Division; Dihydrotestosterone; Flutamide; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; Membrane Transport Proteins; Nitriles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tosyl Compounds; Tumor Cells, Cultured | 1999 |
Relative potency of bicalutamide (Casodex) and flutamide (Eulexin)
Topics: Androgen Antagonists; Anilides; Animals; Flutamide; Humans; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1999 |
Effects of androgens and antiandrogens on the quantitative immunohistochemistry of gonadotrope cells in prepubertal male rats.
Topics: Androgen Antagonists; Anilides; Animals; Dihydrotestosterone; Flutamide; Follicle Stimulating Hormone; Immunohistochemistry; Luteinizing Hormone; Male; Nitriles; Orchiectomy; Pituitary Gland; Rats; Rats, Sprague-Dawley; Sexual Maturation; Tosyl Compounds | 1999 |
Short-term and long-term histologic effects of castration and estrogen treatment on breast tissue of 14 male-to-female transsexuals in comparison with two chemically castrated men.
Topics: Adult; Aged; Androgen Antagonists; Anilides; Breast; Castration; Cyproterone Acetate; Estradiol Congeners; Ethinyl Estradiol; Female; Flutamide; Follow-Up Studies; Gynecomastia; Humans; Male; Mastectomy, Subcutaneous; Metaplasia; Nitriles; Orchiectomy; Time Factors; Tosyl Compounds; Transsexualism | 2000 |
Specific recognition of androgens by their nuclear receptor. A structure-function study.
Topics: Amino Acid Sequence; Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Anilides; Binding Sites; Computer Simulation; Cyproterone Acetate; Dose-Response Relationship, Drug; Flutamide; Humans; Ligands; Metribolone; Models, Molecular; Molecular Sequence Data; Nitriles; Progesterone; Promegestone; Receptors, Androgen; Sequence Alignment; Tosyl Compounds; Transcriptional Activation | 2000 |
Nondetected tumor (pT0) after prolonged, neoadjuvant treatment of localized prostatic carcinoma.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Flutamide; Humans; Leuprolide; Male; Neoplasm, Residual; Nitriles; Prostate; Prostatectomy; Prostatic Neoplasms; Time Factors; Tosyl Compounds | 2000 |
Ultrastructural and quantitative immunohistochemical changes induced by nonsteroid antiandrogens on pituitary gonadotroph population of prepubertal male rats.
Topics: Androgen Antagonists; Anilides; Animals; Dihydrotestosterone; Flutamide; Follicle Stimulating Hormone; Hormone Replacement Therapy; Immunohistochemistry; Luteinizing Hormone; Male; Microscopy, Electron; Nitriles; Pituitary Gland, Anterior; Rats; Rats, Sprague-Dawley; Secretory Vesicles; Sexual Maturation; Tosyl Compounds | 2001 |
Why phase III trials of maximal androgen blockade versus castration in M1 prostate cancer rarely show statistically significant differences.
Topics: Androgen Antagonists; Anilides; Clinical Trials, Phase III as Topic; Cyproterone Acetate; Factor Analysis, Statistical; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Imidazoles; Imidazolidines; Leuprolide; Male; Meta-Analysis as Topic; Nitriles; Orchiectomy; Prognosis; Prostatic Neoplasms; Research Design; Survival Analysis; Tosyl Compounds; Treatment Outcome | 2001 |
The amino terminus of the human AR is target for corepressor action and antihormone agonism.
Topics: Androgen Antagonists; Anilides; Animals; Catalytic Domain; Cell Line; Cyclic AMP-Dependent Protein Kinases; Cyproterone Acetate; DNA-Binding Proteins; Flutamide; Haplorhini; Humans; Ligands; Male; Nitriles; Nuclear Receptor Co-Repressor 2; Point Mutation; Protein Conformation; Receptors, Androgen; Repressor Proteins; Tosyl Compounds; Transcriptional Activation; Transfection | 2002 |
Low serum testosterone level predicts worse response to endocrine therapy in Japanese patients with metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Anilides; Antineoplastic Agents, Hormonal; Bone Neoplasms; Chlormadinone Acetate; Diethylstilbestrol; Disease Progression; Flutamide; Gonadotropin-Releasing Hormone; Humans; Japan; Male; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Predictive Value of Tests; Prostate-Specific Antigen; Prostatic Neoplasms; Statistics, Nonparametric; Testosterone; Tosyl Compounds | 2002 |
Stabilization of androgen receptor protein is induced by agonist, not by antagonists.
Topics: Androgen Receptor Antagonists; Androgens; Anilides; Animals; Blotting, Northern; Blotting, Western; CHO Cells; Cricetinae; Dihydrotestosterone; Dose-Response Relationship, Drug; Flutamide; Humans; Ligands; Luciferases; Nitriles; Plasmids; Receptors, Androgen; RNA Processing, Post-Transcriptional; Time Factors; Tosyl Compounds; Transcriptional Activation; Transfection; Tumor Cells, Cultured | 2002 |
Acquisition of agonistic properties of nonsteroidal antiandrogens after treatment with oncostatin M in prostate cancer cells.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Calcium-Calmodulin-Dependent Protein Kinases; Chloramphenicol; Cyclic AMP-Dependent Protein Kinases; DNA Primers; Enzyme Inhibitors; Flavonoids; Flutamide; Growth Inhibitors; Humans; Interleukin-6; Male; Nitriles; Oncostatin M; Peptides; Prostatic Neoplasms; Receptors, Androgen; Receptors, Cytokine; Receptors, Oncostatin M; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Tosyl Compounds; Transfection; Tumor Cells, Cultured | 2002 |
Pure antiandrogens disrupt the recruitment of coactivator GRIP1 to colocalize with androgen receptor in nuclei.
Topics: Active Transport, Cell Nucleus; Androgen Antagonists; Androgens; Anilides; Animals; Cell Nucleus; Chlorocebus aethiops; COS Cells; Cyproterone Acetate; Flutamide; Nitriles; Nuclear Receptor Coactivator 2; Receptors, Androgen; Subcellular Fractions; Tosyl Compounds; Transcription Factors; Transcriptional Activation | 2002 |
Bone alkaline phosphatase serum level predicts the response to antiandrogen withdrawal.
Topics: Aged; Alkaline Phosphatase; Androgen Antagonists; Anilides; Flutamide; Humans; Male; Nitriles; Prostate-Specific Antigen; Time Factors; Tosyl Compounds | 2002 |
Pneumonitis associated with nonsteroidal antiandrogens: presumptive evidence of a class effect.
Topics: Adult; Aged; Alveolitis, Extrinsic Allergic; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 2002 |
Key structural features of nonsteroidal ligands for binding and activation of the androgen receptor.
Topics: Anilides; Animals; Cells, Cultured; Flutamide; Haplorhini; Imidazoles; Imidazolidines; Ligands; Nitriles; Rats; Rats, Sprague-Dawley; Receptors, Androgen; Structure-Activity Relationship; Tosyl Compounds; Trail Making Test | 2003 |
Impact of a novel neoadjuvant and adjuvant hormone-deprivation approach on quality of life, voiding function, and sexual function after prostate brachytherapy.
Topics: 5-alpha Reductase Inhibitors; Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Brachytherapy; Chemotherapy, Adjuvant; Diarrhea; Enzyme Inhibitors; Finasteride; Flutamide; Humans; Logistic Models; Male; Nitriles; Penile Erection; Prostatic Neoplasms; Quality of Life; Tosyl Compounds; Treatment Outcome; Urinary Incontinence | 2003 |
Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
Topics: Absorptiometry, Photon; Adenocarcinoma; Aged; Amino Acids; Androgen Antagonists; Androgens; Anilides; Antineoplastic Agents, Hormonal; Biomarkers; Bone Density; Bone Remodeling; Calcium; Drug Therapy, Combination; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Neoplasms, Hormone-Dependent; Nitriles; Orchiectomy; Osteoporosis; Prospective Studies; Prostatic Neoplasms; Testosterone; Tosyl Compounds | 2002 |
Inhibition of fatty acid synthase expression by 1alpha,25-dihydroxyvitamin D3 in prostate cancer cells.
Topics: Androgen Antagonists; Anilides; Calcitriol; Cerulenin; Cycloheximide; Down-Regulation; Enzyme Inhibitors; Fatty Acid Synthases; Flutamide; Gene Expression Regulation, Neoplastic; Humans; Male; Nitriles; Oligonucleotide Array Sequence Analysis; Prostatic Neoplasms; Protein Synthesis Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tosyl Compounds; Tumor Cells, Cultured | 2003 |
Impact of hormone therapy when combined with external beam radiotherapy for early-stage, intermediate-, or high-risk prostate cancer.
Topics: Adenocarcinoma; Aged; Anilides; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Flutamide; Goserelin; Humans; Male; Neoadjuvant Therapy; Nitriles; Prostatic Neoplasms; Survival Analysis; Tosyl Compounds | 2003 |
Bioassay of steroid hormone agonist and antagonist activities of anti-androgens on mammary gland, seminal vesicles and spleen of male mice.
Topics: Androgen Antagonists; Anilides; Animals; Animals, Outbred Strains; Biological Assay; Chlormadinone Acetate; Cyproterone Acetate; Drug Therapy, Combination; Estradiol; Flutamide; Male; Mammary Glands, Animal; Mice; Mice, Inbred C3H; Nitriles; Norethindrone; Norethindrone Acetate; Orchiectomy; Progesterone; Seminal Vesicles; Spleen; Steroids; Tosyl Compounds | 2003 |
Androgen dependent regulation of bacillus Calmette-Guerin induced interleukin-6 expression in human transitional carcinoma cell lines.
Topics: Androgen Antagonists; Anilides; Autocrine Communication; BCG Vaccine; Carcinoma, Transitional Cell; Dihydrotestosterone; Dose-Response Relationship, Drug; Flutamide; Gene Expression; Genes, Reporter; Humans; Neoplasms, Hormone-Dependent; NF-kappa B; Nitriles; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tosyl Compounds; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Vaccines, Attenuated | 2003 |
Hormonal and morphologic evaluation of the effects of antiandrogens on the blood supply of the rat prostate.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Androgen Antagonists; Anilides; Animals; Capillaries; Chlormadinone Acetate; Dihydrotestosterone; Enzyme Inhibitors; Finasteride; Flutamide; Gonadotropin-Releasing Hormone; Hormone Antagonists; Male; Microcirculation; Nitriles; Prazosin; Prostate; Rats; Rats, Wistar; Sulfonamides; Tamsulosin; Testosterone; Tosyl Compounds | 2003 |
[Comparative study of the effect of complete prolonged neoadjuvant hormonal blockade versus standard hormonal blockade].
Topics: Androgen Antagonists; Anilides; Chemotherapy, Adjuvant; Flutamide; Gonadotropin-Releasing Hormone; Humans; Male; Nitriles; Prostatectomy; Prostatic Neoplasms; Retrospective Studies; Time Factors; Tosyl Compounds | 2003 |
Prognosis of stage pT0 after prolonged neoadjuvant endocrine therapy of prostate cancer: a matched-pair analysis.
Topics: Anilides; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Flutamide; Follow-Up Studies; Goserelin; Humans; Leuprolide; Male; Matched-Pair Analysis; Neoplasm Staging; Nitriles; Prognosis; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Time Factors; Tosyl Compounds | 2004 |
Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Flutamide; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Prostatic Neoplasms; Substance Withdrawal Syndrome; Survival Rate; Tosyl Compounds; Treatment Failure | 2004 |
Osteoporosis and spinal fractures in men with prostate cancer: risk factors and effects of androgen deprivation therapy.
Topics: Aged; Alcohol Drinking; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Comorbidity; Flutamide; Goserelin; Humans; Male; Multivariate Analysis; Nitriles; Osteoporosis; Prostatic Neoplasms; Retrospective Studies; Risk Factors; Spinal Fractures; Time Factors; Tosyl Compounds; Vitamin D | 2004 |
Re: The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Cognition; Drug Therapy, Combination; Flutamide; Humans; Leuprolide; Male; Neuropsychological Tests; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 2004 |
Androgen receptor is targeted to distinct subcellular compartments in response to different therapeutic antiandrogens.
Topics: Adenosine Triphosphate; Androgen Antagonists; Androgens; Anilides; Animals; Cell Line, Tumor; Cell Nucleus; COS Cells; Cytoplasm; Cytoskeleton; Electrophoresis, Gel, Two-Dimensional; Flutamide; Humans; Immunoblotting; Male; Mass Spectrometry; Microscopy, Confocal; Microscopy, Fluorescence; Nitriles; Prostatic Neoplasms; Protein Transport; Receptors, Androgen; Subcellular Fractions; Tosyl Compounds; Transfection | 2004 |
5alpha-dihydrotestosterone inhibits 1alpha,25-dihydroxyvitamin D3-induced expression of CYP24 in human prostate cancer cells.
Topics: Androgen Receptor Antagonists; Androgens; Anilides; Calcitriol; Cycloheximide; Cytochrome P-450 Enzyme System; Dihydrotestosterone; Drug Interactions; Flutamide; Gene Expression Regulation, Enzymologic; Humans; Male; Nitriles; Prostatic Neoplasms; Protein Synthesis Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Steroid Hydroxylases; Tosyl Compounds; Tumor Cells, Cultured; Vitamin D3 24-Hydroxylase | 2005 |
Reversibility of androgen deprivation therapy in patients with prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Flutamide; Gonadotropin-Releasing Hormone; Humans; Luteinizing Hormone; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Testosterone; Tosyl Compounds | 2005 |
Three-dimensional structure-activity relationships of nonsteroidal ligands in complex with androgen receptor ligand-binding domain.
Topics: Anilides; Binding Sites; Flutamide; Imidazolidines; Ligands; Models, Molecular; Nitriles; Quantitative Structure-Activity Relationship; Receptors, Androgen; Tosyl Compounds | 2005 |
Impact of hormone therapy on acute radiotherapy toxicity in the treatment of prostate cancer.
Topics: Aged; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Brachytherapy; Cohort Studies; Flutamide; Gastrointestinal Tract; Goserelin; Hormones; Humans; Leuprolide; Male; Middle Aged; Nitriles; Prognosis; Prostatic Neoplasms; Radiation Injuries; Radiotherapy; Radiotherapy Dosage; Regression Analysis; Testosterone; Time Factors; Tosyl Compounds; Treatment Outcome; Urogenital System | 2005 |
Late radiotherapy toxicity after prostate cancer treatment: influence of hormonal therapy.
Topics: Aged; Anilides; Antineoplastic Agents, Hormonal; Flutamide; Gastrointestinal Diseases; Goserelin; Humans; Leuprolide; Male; Male Urogenital Diseases; Nitriles; Prostatic Neoplasms; Radiation Injuries; Time Factors; Tosyl Compounds | 2005 |
Antiandrogens prevent stable DNA-binding of the androgen receptor.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Anilides; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cells, Cultured; Computer Simulation; DNA; DNA-Binding Proteins; DNA, Neoplasm; Flutamide; Green Fluorescent Proteins; Humans; Liver Neoplasms; Male; Metribolone; Nitriles; Prostatic Neoplasms; Receptors, Androgen; Recombinant Fusion Proteins; Tosyl Compounds | 2005 |
Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Drug Resistance, Neoplasm; Flutamide; Humans; Male; Middle Aged; Nitriles; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Tosyl Compounds; Treatment Outcome | 2005 |
Is combined androgen blockade with bicalutamide cost-effective compared with combined androgen blockade with flutamide?
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Flutamide; Humans; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 2005 |
Spontaneous reporting of hepatotoxicity associated with antiandrogens: data from the Spanish pharmacovigilance system.
Topics: Adverse Drug Reaction Reporting Systems; Androgen Antagonists; Anilides; Chemical and Drug Induced Liver Injury; Cyproterone Acetate; Flutamide; Humans; International Classification of Diseases; Liver Diseases; Nitriles; Retrospective Studies; Spain; Time Factors; Tosyl Compounds | 2006 |
Co-activator and co-repressor interplay on the human androgen receptor.
Topics: Androgen Antagonists; Androgen-Binding Protein; Androgens; Anilides; Cyproterone Acetate; Flutamide; Humans; Ligands; Male; Nitriles; Protein Binding; Receptors, Androgen; Repressor Proteins; Response Elements; Time Factors; Tosyl Compounds; Trans-Activators; Transcriptional Activation | 2005 |
DHT and testosterone, but not DHEA or E2, differentially modulate IGF-I, IGFBP-2, and IGFBP-3 in human prostatic stromal cells.
Topics: Androgen Antagonists; Anilides; Cell Proliferation; Cells, Cultured; Dehydroepiandrosterone; Dihydrotestosterone; Estradiol; Flutamide; Gene Expression; Humans; Insulin-Like Growth Factor Binding Protein 2; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor Binding Protein 5; Insulin-Like Growth Factor Binding Proteins; Insulin-Like Growth Factor I; Insulin-Like Growth Factor II; Male; Middle Aged; Nitriles; Prostate; Receptor, IGF Type 1; Stromal Cells; Testosterone; Tosyl Compounds | 2006 |
The limited significance of a longer duration of neoadjuvant hormonal therapy prior to radical prostatectomy for high-risk prostate cancer in Japanese men.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Japan; Leuprolide; Male; Middle Aged; Neoadjuvant Therapy; Nitriles; Preoperative Care; Prostatectomy; Prostatic Neoplasms; Retrospective Studies; Risk Factors; Time Factors; Tosyl Compounds | 2006 |
Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer.
Topics: Aged; Androgen Antagonists; Anilides; Cohort Studies; Flutamide; Humans; Male; Middle Aged; Neoplasm Staging; Nitriles; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Regression Analysis; Risk Factors; Tosyl Compounds; Treatment Outcome | 2006 |
Ligand-specific dynamics of the androgen receptor at its response element in living cells.
Topics: Adenocarcinoma; Androgen Antagonists; Androgens; Anilides; Animals; Cell Line, Tumor; Chromatin Assembly and Disassembly; Cyproterone Acetate; Dihydrotestosterone; Female; Fluorescence Recovery After Photobleaching; Flutamide; Genes, Reporter; Green Fluorescent Proteins; In Situ Hybridization, Fluorescence; Ligands; Luciferases; Mammary Neoplasms, Animal; Mammary Tumor Virus, Mouse; Metribolone; Mice; Microscopy, Video; Mifepristone; Models, Biological; Nitriles; Plasmids; Promoter Regions, Genetic; Receptors, Androgen; Response Elements; Testosterone; Tosyl Compounds; Transcription, Genetic | 2007 |
The androgen receptor T877A mutant recruits LXXLL and FXXLF peptides differently than wild-type androgen receptor in a time-resolved fluorescence resonance energy transfer assay.
Topics: Amino Acid Sequence; Amino Acid Substitution; Androgen Antagonists; Anilides; Animals; Cyproterone Acetate; Dihydrotestosterone; Fluoresceins; Fluorescence Resonance Energy Transfer; Flutamide; Ligands; Mifepristone; Nitriles; Oligopeptides; Rats; Receptors, Androgen; Tosyl Compounds | 2007 |
Non-steroidal antiandrogens act as AF-1 agonists under conditions of high androgen-receptor expression.
Topics: Androgens; Anilides; Dihydrotestosterone; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Flutamide; HeLa Cells; Humans; Male; Nitriles; Prostatic Neoplasms; Receptors, Androgen; Receptors, Interferon; Tosyl Compounds; Transcriptional Activation | 2007 |
Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors.
Topics: Allylestrenol; Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Anilides; Cyproterone Acetate; Flutamide; Humans; Imidazolidines; Male; Models, Molecular; Mutagenesis, Site-Directed; Neoplasms, Hormone-Dependent; Nitriles; Plasmids; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Testosterone; Tosyl Compounds; Transcription, Genetic; Transfection | 2007 |
Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Biopsy, Needle; Drug Resistance, Neoplasm; Drug Therapy, Combination; Endosonography; Flutamide; Follow-Up Studies; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Magnetic Resonance Imaging; Male; Neoplasm Staging; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Tomography, X-Ray Computed; Tosyl Compounds; Treatment Outcome | 2007 |
A novel synthetic compound that interrupts androgen receptor signaling in human prostate cancer cells.
Topics: Androgen Receptor Antagonists; Androgens; Anilides; Antineoplastic Agents; Cell Proliferation; Dihydrotestosterone; Drug Resistance, Neoplasm; Drug Synergism; Flutamide; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Imidazolidines; Male; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Tosyl Compounds; Transcription, Genetic | 2007 |
Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Choice Behavior; Cross-Sectional Studies; Diarrhea; Drug Administration Schedule; Drug Costs; Drug Therapy; Erectile Dysfunction; Flutamide; Gynecomastia; Health Surveys; Hematuria; Humans; Life Expectancy; Male; Middle Aged; Nitriles; Patient Acceptance of Health Care; Patient Satisfaction; Prostatic Neoplasms; Tosyl Compounds | 2008 |
Does small-cell phenotype predict the natural history of prostate cancer? A case study in disease behavior.
Topics: Adenocarcinoma; Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Docetaxel; Estramustine; Etoposide; Flutamide; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Nephrostomy, Percutaneous; Nitriles; Phenotype; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Tosyl Compounds; Transurethral Resection of Prostate; Urinary Diversion | 2007 |
Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Flutamide; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Nitriles; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Risk; Survival Analysis; Testosterone; Tosyl Compounds | 2007 |
Partial androgen suppression consequent to increased secretion of adrenal androgens in a patient with prostate cancer treated with long-acting GnRH agonists.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Androgens; Anilides; Buserelin; Diarrhea; Flutamide; Gastrectomy; Glaucoma; Gonadotropin-Releasing Hormone; Hernia, Hiatal; Humans; Luteinizing Hormone; Male; Nitriles; Peptic Ulcer; Prostate-Specific Antigen; Prostatic Neoplasms; Testosterone; Tosyl Compounds | 2009 |
Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Flutamide; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Substance Withdrawal Syndrome; Survival Analysis; Tosyl Compounds; Treatment Outcome | 2008 |
Design and synthesis of carborane-containing androgen receptor (AR) antagonist bearing a pyridine ring.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Anilides; Animals; Binding, Competitive; Boranes; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Evaluation, Preclinical; Flutamide; Humans; Hydrophobic and Hydrophilic Interactions; Mice; Molecular Structure; NIH 3T3 Cells; Nitriles; Pyridines; Receptors, Androgen; Stereoisomerism; Structure-Activity Relationship; Tosyl Compounds; Transfection | 2008 |
Computationally identified novel diphenyl- and phenylpyridine androgen receptor antagonist structures.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Anilides; Animals; Antineoplastic Agents; Binding, Competitive; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Chlorocebus aethiops; Computer Simulation; Drug Design; Drug Evaluation, Preclinical; Drug Screening Assays, Antitumor; Flutamide; Humans; Male; Models, Molecular; Molecular Structure; Nitriles; Prostatic Neoplasms; Pyridines; Tosyl Compounds | 2008 |
Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment.
Topics: Aged; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Flutamide; Follow-Up Studies; Goserelin; Humans; Leuprolide; Male; Multivariate Analysis; Neoadjuvant Therapy; Neoplastic Cells, Circulating; Nitriles; Prognosis; Prostatectomy; Prostatic Neoplasms; Tosyl Compounds | 2008 |
Functional AR signaling is evident in an in vitro mouse follicle culture bioassay that encompasses most stages of folliculogenesis.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Anilides; Animals; Biological Assay; Cell Culture Techniques; Cells, Cultured; Female; Flutamide; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Nitriles; Ovarian Follicle; Receptors, Androgen; Signal Transduction; Tosyl Compounds | 2009 |
Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.
Topics: Analysis of Variance; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Biopsy; Brachytherapy; Flutamide; Follow-Up Studies; Goserelin; Humans; Iodine Radioisotopes; Leuprolide; Male; Nitriles; Palladium; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Radiotherapy Dosage; Relative Biological Effectiveness; Tosyl Compounds; Treatment Failure | 2009 |
Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy.
Topics: Amino Acid Substitution; Anilides; Antineoplastic Agents; Autopsy; Cycloheximide; DNA Primers; Flutamide; Humans; Lymphatic Metastasis; Male; Mutation; Nitriles; Prostatic Neoplasms; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Tosyl Compounds | 2009 |
Underlying mitochondrial dysfunction triggers flutamide-induced oxidative liver injury in a mouse model of idiosyncratic drug toxicity.
Topics: Alanine Transaminase; Androgen Antagonists; Anilides; Animals; Apoptosis; Dose-Response Relationship, Drug; Flutamide; Hepatocytes; Heterozygote; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mitochondria; Necrosis; Nitriles; Oxidative Stress; Superoxide Dismutase; Systems Biology; Tosyl Compounds | 2009 |
Antiandrogen withdrawal syndrome and alternative antiandrogen therapy associated with the W741C mutant androgen receptor in a novel prostate cancer xenograft.
Topics: Administration, Oral; Androgen Antagonists; Androgens; Anilides; Animals; Antineoplastic Agents, Hormonal; Cysteine; Drug Administration Schedule; Flutamide; Humans; Male; Mice; Mutation; Neoplasm Transplantation; Nitriles; Prostatic Neoplasms; Receptors, Androgen; Retreatment; Substance Withdrawal Syndrome; Tosyl Compounds; Transplantation, Heterologous; Tryptophan | 2010 |
Systematic structure-function analysis of androgen receptor Leu701 mutants explains the properties of the prostate cancer mutant L701H.
Topics: Androgen Antagonists; Anilides; Blotting, Western; Cell Line, Tumor; Cyproterone Acetate; Dihydrotestosterone; Flutamide; Humans; Hydrocortisone; Hydrophobic and Hydrophilic Interactions; Male; Mutation; Nitriles; Progesterone; Prostatic Neoplasms; Protein Structure, Secondary; Receptors, Androgen; Steroids; Structure-Activity Relationship; Tosyl Compounds | 2010 |
Efficacy of maximal androgen blockade versus castration alone in the treatment of advanced prostate cancer: a retrospective clinical experience from a Chinese medical centre.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; China; Combined Modality Therapy; Disease-Free Survival; Flutamide; Gonadotropin-Releasing Hormone; Humans; Kaplan-Meier Estimate; Male; Multivariate Analysis; Neoplasm Metastasis; Nitriles; Orchiectomy; Prostatic Neoplasms; Retrospective Studies; Tosyl Compounds | 2010 |
Alternative antiandrogen therapy in patients with castration-resistant prostate cancer: a single-center experience.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Chlormadinone Acetate; Cohort Studies; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Therapy, Combination; Flutamide; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Risk Assessment; Survival Analysis; Tosyl Compounds; Treatment Failure | 2010 |
Hydroxyflutamide enhances cellular sensitivity to 5-fluorouracil by suppressing thymidylate synthase expression in bicalutamide-resistant human prostate cancer cells.
Topics: Androgen Antagonists; Anilides; Antimetabolites, Antineoplastic; Carcinoma; Cell Line, Tumor; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; Fluorouracil; Flutamide; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Male; Models, Biological; Neoplasms, Hormone-Dependent; Nitriles; Prostatic Neoplasms; Thymidylate Synthase; Tosyl Compounds | 2011 |
Clinical efficacy of primary combined androgen blockade for Japanese men with clinically localized prostate cancer unsuitable for local definitive treatment: a single institution experience.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chlormadinone Acetate; Disease-Free Survival; Flutamide; Follow-Up Studies; Goserelin; Humans; Japan; Kaplan-Meier Estimate; Leuprolide; Male; Middle Aged; Neoplasm Staging; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Tosyl Compounds; Treatment Outcome | 2011 |
[Alternative antiandrogen therapy with flutamide in patients with castration-resistant prostate cancer : a single center experience].
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Castration; Flutamide; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome | 2011 |
[Improvement of lower urinary tract symptoms in patients with prostate cancer treated with maximal androgen blockade].
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Flutamide; Humans; Male; Middle Aged; Neoplasm Staging; Nitriles; Prostatic Neoplasms; Tosyl Compounds; Urination Disorders | 2011 |
Upfront androgen deprivation therapy with salvage radiation may improve biochemical outcomes in prostate cancer patients with post-prostatectomy rising PSA.
Topics: Analysis of Variance; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-Free Survival; Flutamide; Goserelin; Humans; Leuprolide; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Nitriles; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Radiotherapy Dosage; Retrospective Studies; Salvage Therapy; Seminal Vesicles; Tosyl Compounds | 2012 |
Biopsy Gleason score and the duration of testosterone suppression among men treated with external beam radiation and 6 months of combined androgen blockade.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Drug Therapy, Combination; Flutamide; Humans; Male; Middle Aged; Neoplasm Grading; Nitriles; Prospective Studies; Prostate; Prostatic Neoplasms; Testosterone; Tosyl Compounds | 2012 |
[Effect of change to flutamide for prostate cancer patient who developed breast pain during bicalutamide treatment (BIP-F study)].
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Drug Administration Schedule; Drug Substitution; Flutamide; Humans; Male; Mastodynia; Middle Aged; Nitriles; Pain Measurement; Prostatic Neoplasms; Surveys and Questionnaires; Tosyl Compounds; Treatment Outcome | 2014 |
Docetaxel followed by abiraterone in metastatic castration-resistant prostate cancer: efficacy and predictive parameters in a large single center cohort.
Topics: Aged; Androgen Antagonists; Androstenes; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Buserelin; Cohort Studies; Disease-Free Survival; Docetaxel; Flutamide; Humans; Leuprolide; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Nitriles; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Tosyl Compounds; Treatment Outcome; Triptorelin Pamoate | 2015 |
Inhibition of Stat5a/b Enhances Proteasomal Degradation of Androgen Receptor Liganded by Antiandrogens in Prostate Cancer.
Topics: Androgen Antagonists; Androgens; Anilides; Benzamides; Cell Line, Tumor; Cell Survival; Flutamide; Gene Expression Regulation, Neoplastic; Humans; Ligands; Male; Nitriles; Phenylthiohydantoin; Promoter Regions, Genetic; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Proteasome Endopeptidase Complex; Receptors, Androgen; Signal Transduction; STAT5 Transcription Factor; Tosyl Compounds; Tumor Suppressor Proteins | 2015 |
Antiandrogens act as selective androgen receptor modulators at the proteome level in prostate cancer cells.
Topics: Amino Acid Sequence; Androgen Antagonists; Anilides; Cell Line, Tumor; Cyproterone Acetate; Flutamide; Gene Expression Regulation, Neoplastic; Humans; Male; Molecular Sequence Annotation; Molecular Sequence Data; Mutation; Nandrolone; Neoplasm Proteins; Nitriles; Prostate; Proteome; Receptors, Androgen; Signal Transduction; Tosyl Compounds | 2015 |
Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients.
Topics: Androgen Receptor Antagonists; Anilides; Benzamides; DNA; Drug Resistance, Neoplasm; Flutamide; High-Throughput Nucleotide Sequencing; Humans; Male; Mutation; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Tosyl Compounds | 2016 |
The fluorescent two-hybrid assay for live-cell profiling of androgen receptor modulators.
Topics: Androgen Antagonists; Androgens; Androstadienes; Androstenes; Anilides; Animals; Benzamides; Benzimidazoles; Biological Assay; Cell Line; Cricetinae; Dihydrotestosterone; Flutamide; HEK293 Cells; Humans; Male; Microscopy, Fluorescence; Mutation; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Receptors, Androgen; Tosyl Compounds; Transcription Factors; Two-Hybrid System Techniques | 2017 |
Corepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen.
Topics: Androgen Antagonists; Anilides; Cell Line, Tumor; Cell Proliferation; Dihydrotestosterone; Flutamide; Gene Expression Regulation, Neoplastic; Humans; Male; Mutation; Nitriles; Nuclear Receptor Coactivators; Prostatic Neoplasms; Receptors, Androgen; Tosyl Compounds | 2016 |
Adverse Health Effects of Intermittent vs Continuous Androgen Deprivation Therapy for Metastatic Prostate Cancer: Relating 33 Years of Patient Clinical Care.
Topics: Androgen Antagonists; Androgens; Anilides; Drug-Related Side Effects and Adverse Reactions; Flutamide; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Libido; Male; Medicare; Neoplasm Metastasis; Nitriles; Penis; Prostatic Neoplasms; Tosyl Compounds; United States | 2016 |
Enzalutamide inhibits androgen receptor-positive bladder cancer cell growth.
Topics: Androgen Antagonists; Anilides; Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dihydrotestosterone; Down-Regulation; Flutamide; Humans; Interleukin-6; Male; Matrix Metalloproteinase 2; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Transplantation; Nitriles; Phenylthiohydantoin; Receptors, Androgen; RNA; Tosyl Compounds; Transcription, Genetic; Urinary Bladder Neoplasms | 2016 |
Efficacy of Immediate Switching from Bicalutamide to Flutamide as Second-Line Combined Androgen Blockade.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Drug Administration Schedule; Flutamide; Humans; Male; Middle Aged; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Reproducibility of Results; Retrospective Studies; Sensitivity and Specificity; Tosyl Compounds; Treatment Outcome | 2016 |
Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Arrhythmias, Cardiac; California; Cardiovascular Diseases; Cohort Studies; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Heart Failure; Humans; Imidazolidines; Leuprolide; Male; Middle Aged; Multivariate Analysis; Neoplasm Grading; Nitriles; Proportional Hazards Models; Prospective Studies; Prostatic Neoplasms; Risk Factors; Tosyl Compounds | 2017 |
Metabolic Hydrolysis of Aromatic Amides in Selected Rat, Minipig, and Human In Vitro Systems.
Topics: Acetaminophen; Acetanilides; Amides; Anilides; Animals; Carboxylesterase; Flutamide; Hepatocytes; Humans; Hydrolysis; Lidocaine; Male; Microsomes, Liver; Niclosamide; Nitriles; Prilocaine; Primary Cell Culture; Propanil; Rats; Rats, Sprague-Dawley; Subcellular Fractions; Swine; Swine, Miniature; Tosyl Compounds | 2018 |
Response to flutamide, as second-line therapy after bicalutamide, predicts efficacy of abiraterone, not that of enzalutamide.
Topics: Aged; Aged, 80 and over; Androstenes; Anilides; Antineoplastic Agents; Benzamides; Disease-Free Survival; Flutamide; Humans; Male; Middle Aged; Nitriles; Outcome Assessment, Health Care; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Tosyl Compounds | 2018 |
Androgen deprivation therapy and depression in men with prostate cancer treated with definitive radiation therapy.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Depression; Depressive Disorder; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Hospitalization; Humans; Imidazolidines; Leuprolide; Male; Mental Health Services; Middle Aged; Nitriles; Oligopeptides; Prostatic Neoplasms; Radiotherapy; Retrospective Studies; Suicide; Tosyl Compounds | 2019 |
How can we improve the physical stability of co-amorphous system containing flutamide and bicalutamide? The case of ternary amorphous solid dispersions.
Topics: Acrylates; Anilides; Crystallization; Drug Delivery Systems; Drug Stability; Excipients; Flutamide; Methylmethacrylate; Nitriles; Polymers; Povidone; Solubility; Tosyl Compounds | 2019 |
Structural Dynamics of Agonist and Antagonist Binding to the Androgen Receptor.
Topics: Androgen Receptor Antagonists; Androgens; Anilides; Binding Sites; Dihydrotestosterone; Flutamide; Humans; Molecular Dynamics Simulation; Nitriles; Receptors, Androgen; Testosterone; Tosyl Compounds | 2019 |
Predictors of poor response to first-generation anti-androgens as criteria for alternate treatments for patients with non-metastatic castration-resistant prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Chlormadinone Acetate; Flutamide; Humans; Male; Middle Aged; Nitriles; Patient Selection; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Tosyl Compounds | 2020 |
Sequential Use of Androgen Receptor Axis-targeted Agents in Chemotherapy-naive Castration-resistant Prostate Cancer: A Multicenter Retrospective Analysis With 3-Year Follow-up.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Androgen Receptor Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Flutamide; Follow-Up Studies; Humans; Kallikreins; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Tosyl Compounds | 2020 |
A case of advanced prostate cancer controlled for the long term by flutamide after bicalutamide failure.
Topics: Aged; Anilides; Disease Progression; Flutamide; Humans; Male; Nitriles; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Temperature; Tosyl Compounds | 2019 |
Analysis of adverse event of interstitial lung disease in men with prostate cancer receiving hormone therapy using the Food and Drug Administration Adverse Event Reporting System.
Topics: Adverse Drug Reaction Reporting Systems; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Goserelin; Humans; Lung Diseases, Interstitial; Male; Prostatic Neoplasms; United States; United States Food and Drug Administration | 2023 |
Mechanism of non-steroidal anti-androgen-induced liver injury: Reactive metabolites of flutamide and bicalutamide activate inflammasomes.
Topics: Androgen Antagonists; Anilides; Chemical and Drug Induced Liver Injury, Chronic; Flutamide; Humans; Inflammasomes; Male; Nitriles; Prostatic Neoplasms | 2023 |